as 12-18-2024 12:30pm EST
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
More About Our AKRO ML Model...
What kind of parameters do you use to train AKRO stocks ML model?
To train our stocks AKRO ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
How often do you update AKRO ML model?
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Why is the accuracy of your AKRO model low?
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
How can I provide and share more data with you to increase your ML model accuracy?
We would greatly appreciate your contribution. Please send an email to [email protected]
Do you offer an ML model for shorter time periods, such as 5 minutes or 15 minutes?
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Can I rely on your ML model to make financial decisions regarding buying or selling stocks, or is it only intended for learning purposes?
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Share on Social Networks:
Disclaimer
Our AKRO ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"AKRO Forecast & Prediction for December 18, 2024 Akero Therapeutics Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.